Organovo Announces Postponement of Annual Meeting of Stockholders
September 06 2022 - 8:05AM
Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage
biotechnology company that is focusing on building high fidelity,
3D tissues that recapitulate key aspects of human disease (the
“Company”), today announced that its 2022 Annual Meeting of
Stockholders (the “2022 Annual Meeting”) that was scheduled to be
held at 9:00AM (Pacific Time) on Wednesday, September 7, 2022 has
been postponed to October 12, 2022 at 9:00AM (Pacific Time), a date
determined by the Company’s board of directors. The Company’s board
of directors also established a new record date for the 2022 Annual
Meeting, and based on this record date, the Company will deliver a
new notice of the 2022 Annual Meeting to stockholders entitled to
receive notice of such meeting. The new record date for the 2022
Annual Meeting is September 7, 2022. The 2022 Annual Meeting will
still be conducted virtually via live webcast at
www.virtualshareholdermeeting.com/ONVO2022.
To date, the Company has received
proxies from less than thirty-five percent (35%) as of the prior
July 15, 2022 record date and has therefore postponed the 2022
Annual Meeting in an effort to allow its stockholders additional
time to consider the matters to be presented at the 2022 Annual
Meeting, to encourage greater stockholder participation and to give
the Company’s Board of Directors additional time to further address
and consider stockholder input. The Company plans to promptly file
with the Securities and Exchange Commission and mail an amended
definitive proxy statement, which will include a new notice of the
2022 Annual Meeting and contain additional information about the
2022 Annual Meeting.
About Organovo
Organovo is an early-stage biotechnology company
that is developing and utilizing highly customized 3D human tissues
as dynamic models of healthy and diseased human biology for drug
development. The company’s proprietary technology is being used to
build functional 3D human tissues that mimic key aspects of native
human tissue composition, architecture, function and
disease. Organovo’s advances include cell type-specific
compartments, prevalent intercellular tight junctions, and the
formation of microvascular structures. Management believes these
attributes can enable critical complex, multicellular disease
models that can be used to develop clinically effective drugs for
selected therapeutic areas. For more information
visit Organovo's website at www.organovo.com.
Forward Looking Statements
Any statements contained in this press release
that do not describe historical facts constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. These risks and
uncertainties and other factors are identified and described in
more detail in the Company’s filings with the SEC, including
its Annual Report on Form 10-K filed with
the SEC on June 10, 2022, as such risk factors are
updated in its most recently filed Quarterly Report on Form 10-Q
filed with the SEC on August 11, 2022. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that the Company may issue in the future. Except as required by
applicable law, including the securities laws of the United
States, the Company does not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
Investor Contact
Amato and Partners, LLCInvestor Relations
Counseladmin@amatoandpartners.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Jul 2023 to Jul 2024